ContraFect to Present at the 2013 Stifel Healthcare Conference

ContraFect to Present at the 2013 Stifel Healthcare Conference

ID: 293903

(firmenpresse) - YONKERS, NY -- (Marketwired) -- 09/05/13 -- , developing biotherapeutics for life-threatening infectious diseases, today announced that Robert C. Nowinski, the Company's founder and chief executive officer and Julia P. Gregory, the Company's executive vice president and chief financial officer, will present a corporate overview at the 2013 Stifel Healthcare Conference in Boston, MA, on Thursday, September 12th at 8:35 AM ET. Dr. Nowinski and Ms. Gregory will discuss the Company's novel approach to drug resistant staph infections and clinical plans for its lead product, CF-301.



ContraFect Corporation is a biotechnology company pioneering the use of Lysins and Monoclonal Antibodies to treat life-threatening infectious diseases. ContraFect's initial products include agents to treat diseases such as MRSA (drug-resistant staphylococcus bacteria) and influenza. Its scientific strategy focuses on the use of combination therapies, where it believes that the company's products will overcome high rates of mutation and resistance observed in microbes.



The 2013 Healthcare Conference will address trends in biotechnology, healthcare, major and specialty pharmaceuticals, medical devices and senior housing. Over 1,000 investors and 150 companies are expected to attend this year. In addition to company presentations, Stifel will once again include physician panels, pairing their research analysts with both prominent members of the academic community and executives from leading companies.

Safe Harbor Statement

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events that involve risks and uncertainties These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with our ability to obtain additional funds, obtain and maintain all necessary patents and licenses, meet applicable regulatory standards and receive required regulatory approvals, manufacture or commercialize our products at reasonable costs and compete with other products and market our products in a profitable manner. We assume no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.









For more information, contact:
Barry Kappel, Ph.D., MBA
VP Business Development
Tel: 914-207-2300
E-Mail:
or visit:

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Plandai Biotechnology, Inc. Announces Commencement of Clinical Trials Using Phytofare Topical Product FINR Emerges From Chapter Eleven
Bereitgestellt von Benutzer: Marketwired
Datum: 05.09.2013 - 13:13 Uhr
Sprache: Deutsch
News-ID 293903
Anzahl Zeichen: 0

contact information:
Town:

YONKERS, NY



Kategorie:

Hospitals, Facilities and Providers



Diese Pressemitteilung wurde bisher 192 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ContraFect to Present at the 2013 Stifel Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

ContraFect Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von ContraFect Corporation



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z